A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Latest Information Update: 12 Feb 2025
Price :
$35 *
At a glance
- Drugs Ivonescimab (Primary)
- Indications Carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- Acronyms I-MAC
- 06 Feb 2025 New trial record